This application requests continued funding for our project to investigate the role of acid ceramidase (AC) in mammalian development and disease pathogenesis. During the previous funding period we have: a) shown that AC is essential for embryo survival beyond the 2-cell stage, b) demonstrated that AC is a critical component of oocyte development, and can be used to prevent oocyte and embryo apoptosis in vitro, c) revealed a novel, autocatalytic mechanism of AC processing and activation, and identified a new class of AC inhibitors, and d) constructed """"""""floxed"""""""" AC conditional knockout mice carrying an inducible Cre recombinase (ACcKO/CreTM), and shown that viable ACKO-/- mice can be produced from these animals following tamoxifen injection. In the upcoming funding period we will extend these findings by pursuing the following two, interrelated aims: 1) Construct &characterize the first viable mouse models of AC deficiency. We will continue to use the ACcKO/CreTM mice to induce the ubiquitous knockout of AC activity at different stages of embryogenesis and after birth. We will also breed ACcKO mice to cell-specific (macrophage and Purkinje cell) Cre mice, and use these animals to evaluate the cell-specific functions of AC. The resulting AC deficient mice and embryos will be characterized pathologically, biochemically, and (for those that survive) clinically. In the event that the mice we obtain from these experiments do not have a phenotype that is clinically relevant to human AC deficiency (Farber disease), we will also create """"""""hypomorph"""""""" mice using a mutation """"""""knock-in"""""""" strategy. The goal of these studies is to gain further insights into the role of AC in mammalian development and disease pathogenesis, and to provide researchers with the first viable models of AC deficiency. 2) Further explore the in vivo role of AC in oocyte development. Oocytes are an excellent model for the study of mammalian apoptosis, and our work during the previous funding period has shown that AC is critical to this process. To pursue these findings further, three different Cre mice (GDF9-Cre, ZP3-Cre and Msx2-Cre) will be used to inactivate AC at different stages of folliculogenesis after breeding to the ACcKO mice produced in aim 1. Follicle morphology, as well as the number of oocytes retrieved following superovulation and their stage of development (GV, MI, MII), fertilization capacity, and apoptosis rates will be determined and compared. We will also use TM to inactivate AC in ovarian tissue, and study the uptake and trafficking of recombinant AC by mature oocytes. The goal of these studies is to gain a more complete understanding of AC's role in oocyte development, and to provide a deeper mechanistic appreciation of how AC influences in vitro maturation and fertilization.

Public Health Relevance

AC is a key enzyme in the regulation of sphingolipid metabolism and signaling, and abnormal AC expression has been observed in many human diseases. Our previous work has provided many of the essential research tools needed to study this enzyme, and revealed its critical role in early development. The research we are proposing in the upcoming funding period will continue to provide important new information about this protein, and should impact a wide range of translational medicine disciplines (e.g., lysosomal disease research, fertility, sphingolipid signaling, etc).

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Therapeutic Approaches to Genetic Diseases (TAG)
Program Officer
Mckeon, Catherine T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Schools of Medicine
New York
United States
Zip Code
He, Xingxuan; Dworski, Shaalee; Zhu, Changzhi et al. (2017) Enzyme replacement therapy for Farber disease: Proof-of-concept studies in cells and mice. BBA Clin 7:85-96
Dworski, Shaalee; Lu, Ping; Khan, Aneal et al. (2017) Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis 1863:386-394
Schuchman, Edward H (2016) Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. Biochim Biophys Acta 1862:1459-71
Frohbergh, M E; Guevara, J M; Grelsamer, R P et al. (2016) Acid ceramidase treatment enhances the outcome of autologous chondrocyte implantation in a rat osteochondral defect model. Osteoarthritis Cartilage 24:752-62
Alayoubi, Abdulfatah M; Wang, James C M; Au, Bryan C Y et al. (2013) Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med 5:827-42
Simonaro, Calogera M; Sachot, Sylvain; Ge, Yi et al. (2013) Acid ceramidase maintains the chondrogenic phenotype of expanded primary chondrocytes and improves the chondrogenic differentiation of bone marrow-derived mesenchymal stem cells. PLoS One 8:e62715
Eliyahu, Efrat; Shtraizent, Nataly; Shalgi, Ruth et al. (2012) Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility. Cell Physiol Biochem 30:735-48
Desnick, R J; Schuchman, E H (2012) Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 13:307-35
Eliyahu, Efrat; Shtraizent, Nataly; He, Xingxuan et al. (2011) Identification of cystatin SA as a novel inhibitor of acid ceramidase. J Biol Chem 286:35624-33
Eliyahu, Efrat; Shtraizent, Nataly; Martinuzzi, Kurt et al. (2010) Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. FASEB J 24:1229-38

Showing the most recent 10 out of 27 publications